Boston Scientific Corporation develops, manufactures and markets medical devices that are used in a range of interventional medical specialties. Products During 2015, the company’s products were offered for sale by seven core businesses - Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology. Cardiovascular Interventional Cardiology Drug-Eluting Coronary Stent Systems The company markets the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System featuring an ultra-thin abluminal (outer) bioabsorbable polymer coating. The SYNERGY Stent is unique in that both its proprietary polymer and everolimus drug coating dissipate by three months. In addition, the company markets the Promus PREMIER, Promus Element and Promus Element Plus everolimus-eluting stents. Core Coronary Technology The company markets a line of products used to treat patients with atherosclerosis, a principal cause of coronary artery obstructive disease, which is characterized by a thickening of the walls of the coronary arteries and a narrowing of arterial openings caused by the progressive development of deposits of plaque. Its product offerings include balloon catheters, rotational atherectomy systems, guide wires, guide catheters, embolic protection devices, crossing and re-entry devices for the treatment of chronically occluded coronary vessels and diagnostic catheters used in percutaneous transluminal coronary angioplasty procedures. Intravascular Imaging Systems The company markets a family of intravascular catheter-directed ultrasound imaging catheters and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels. Its Intravascular Ultrasound Imaging catheter, OptiCross, has been launched in all major markets worldwide. The iLab Ultrasound Imaging System continues as the company’s primary console and is compatible with its line of imaging catheters. In addition, the company’s Polaris software designed to run on the iLab System has been approved and launched in the United States (U.S.) and Europe and has been approved in Japan. The iLab System is designed to improve the diagnosis and treatment of blocked vessels and heart disorders. Further, these systems have been placed in cardiology labs worldwide, which provide an installed base through which the company expects to launch new products, including an integrated Fractional Flow Reserve device. Structural Heart Therapies Through the acquisition of Sadra Medical, Inc. (Sadra) in January 2011, the company has developed a repositionable and retrievable device, the Lotus Valve System, for transcatheter aortic valve replacement (TAVR) to treat patients with severe aortic stenosis. The Lotus Valve System is CE-marked in the European Union (EU) and in the U.S., it is an investigational device Through the acquisition of Atritech, Inc. (Atritech) in March 2011, the company has developed a novel device, the Watchman Left Atrial Appendage Closure Device, designed to close the left atrial appendage in patients with atrial fibrillation who are at risk for ischemic stroke. Peripheral Interventions The company sells various products designed to treat patients with peripheral disease (disease which appears in blood vessels other than in the heart and in the biliary tree), including a line of medical devices used in percutaneous transluminal angioplasty (PTA) and peripheral vascular stenting. Its peripheral product offerings include stents, balloon catheters, wires, peripheral embolization devices and vena cava filters. The company’s peripheral angioplasty balloon technology includes its next-generation Mustang PTA balloon; its Coyote balloon catheter, a deliverable and ultra-low profile balloon dilatation catheter designed for a range of peripheral angioplasty procedures; and its Charger PTA Balloon Catheter, a 0.035 inch percutaneous transluminal angioplasty balloon catheter designed for post-stent dilatation, as well as conventional balloon angioplasty to open blocked peripheral arteries. With the company’s Coyote, Mustang a
boston scientific corp (BSX:New York)
300 Boston Scientific Way
Marlborough, MA 01752
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content.
|No competitor information is available for BSX.|
|View Industry Companies|
Sponsored Financial Commentaries
To contact BOSTON SCIENTIFIC CORP, please visit www.bostonscientific.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.